反相色谱 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
=== Military === In 2009, U.S. Embassy sources have reported that Houthis used increasingly more sophisticated tactics and strategies in their conflict with the government as they gained more experience, and that they fought with religious fervor.
== Formulation == Dakin's original solution contained sodium hypochlorite (0.4% to 0.5%), prepared by treating calcium hypochlorite with sodium carbonate ("washing soda"). The solution left after removal of the insoluble calcium carbonate still contained some soda. Boric acid (4%) was then added as a buffering agent to maintain a pH of between 9 and 10. Dakin found that alkalinity outside this range was too irritating. The solution, while unstable, remains effective for at least a week, if made to the correct pH. Other formulations have been developed over time. In 1916, Marcel Daufresne substituted sodium bicarbonate for Dakin's boric acid as buffering agent. This formulation is the basis of current commercial products. The concentration chosen by Dakin (0.5%) was the maximum highest concentration found tolerable to the skin. It is the concentration recommended by the U.S. Centers for Disease Control (CDC) as a household disinfectant. In one study, bactericidal effects of sodium hypochlorite solution were observed at concentrations as low as 0.025%, without any tissue toxicity in vivo or in vitro. It recommended that concentration be adopted as a "modified Dakin's solution" for wound dressing. Currently, various concentrations are sold for wound cleansing including Anasept (0.057%), 1/4 strength Dakin's (0.125%), and Di-Dak-Sol or Dakin's Wound Cleanser (0.0125%) which is 1/40 strength.
Marvel Comics editor-in-chief Roy Thomas wanted to create a Canadian superhero and decided that wolverines were a typical Canadian animal that could inspire such a hero. He asked artist John Romita Sr. and writer Len Wein to devise a character of Canadian origin named Wolverine. Romita designed Wolverine's costume. Wolverine first appeared in the final "teaser" panel of The Incredible Hulk #180 (cover-dated October 1974), written by Wein and penciled by Herb Trimpe. The character then appeared in a number of advertisements in various Marvel Comics publications before making his first major appearance in The Incredible Hulk #181 (November 1974), again by the Wein–Trimpe team. In 2009, Trimpe said he "distinctly remembers" Romita's sketch and that, according to him, Romita and Wein "sewed the monster together [while he] shocked it to life". According to him, Wolverine was initially conceived as a minor character and there were no plans for his continuing popularity. Though sometimes credited as co-creator, Trimpe denied having had any role in Wolverine's creation. The character's introduction was ambiguous, revealing little beyond his being a superhuman agent of the Canadian government. He appears briefly in the following issue's conclusion to the story. Wolverine's next appearance was in Giant-Size X-Men (May 1975), written by Wein and penciled by Dave Cockrum, in which he is recruited for a new team of X-Men to rescue the original group. Gil Kane illustrated the cover artwork but drew Wolverine's mask with larger headpieces.
A small combination of these enhancer-bound transcription factors, when brought close to a promoter by a DNA loop, govern transcription level of the target gene. Mediator (a complex usually consisting of about 26 proteins in an interacting structure) communicates regulatory signals from enhancer DNA-bound transcription factors directly to the RNA polymerase II (pol II) enzyme bound to the promoter. Enhancers, when active, are generally transcribed from both strands of DNA with RNA polymerases acting in two different directions, producing two eRNAs as illustrated in the figure. An inactive enhancer may be bound by an inactive transcription factor. Phosphorylation of the transcription factor may activate it and that activated transcription factor may then activate the enhancer to which it is bound (see small red star representing phosphorylation of transcription factor bound to enhancer in the illustration). An activated enhancer begins transcription of its RNA before activating transcription of messenger RNA from its target gene.
Sources: en.wikipedia.org
=== Beta-blockers === Many of the common symptoms of hyperthyroidism, such as palpitations, trembling, and anxiety, are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing the rapid pulse associated with palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above, and more permanent treatment takes place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but rather, they treat or reduce only symptoms of the condition. Some minimal effect on thyroid hormone production also comes with propranolol, which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism, such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some, though minimal, therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism. Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroidism.
== See also == Biological Stain Commission: Third-party quality control and certification of stains Cytology: the study of cells Histology: the study of tissues Immunohistochemistry: the use of antisera to label specific antigens Ruthenium(II) tris(bathophenanthroline disulfonate), a protein dye. Vital stain: stains that do not kill cells PAGE: separation of protein molecules Barium enema - a type of in vivo stain that creates contrast in the x-ray part of the light spectrum Diaphonization
Instead of in the liquid phase, the dehydrochlorination may also be carried out in the gas phase on a zinc chloride impregnated catalyst in a fluidized bed reactor at 350-500 °C. The seemingly simple reaction yields only 70 to 80% of impure end product due to a variety of side reactions. For example, in the chlorination of ethylene carbonate in substance or solution, 2-chloroacetaldehyde, polychlorinated ethylene carbonate and chlorinated ring-opening products are formed besides others. The separation of the by-products from the final product by distillation by thin-film evaporator, fractional recrystallization or zone melting is very expensive. The content of by-products can be reduced by stirring with sodium borohydride or urea at elevated temperature. However, the purification is complicated by the pronounced thermolability of vinylene carbonate, as it decomposes at temperatures above 80 °C within minutes. Highly pure vinylene carbonate can be obtained in yields of more than 70% by optimizing the chlorination conditions to suppress the formation of by-products and a combination of several gentle purification processes. The tendency of the liquid vinylene carbonate to polymerize is suppressed by addition of inhibitors such as butylhydroxytoluene (BHT).
=== bai Operon Mechanism === Deconjugation: Before primary bile acids reach the bai operon and undergo 7ɑ-dehydroxylation they must be deconjugated from taurine or glycine by a bile salt hydrolase enzyme.> baiG (H+-dependent bile acid transporter): baiG encodes a bile acid transporter protein that allows bacteria to take up unconjugated bile acids for 7ɑ-dehydroxylation. baiB (bile-acid CoA ligase): The first step of primary bile acid 7ɑ-dehydroxylation is carried out by baiB, which facilitates the formation of a bile acid-CoA thioester intermediate. Simply put, this enzyme replaces a hydroxyl (-OH) group with a thioester-CoA (-SCoA) group. This reaction is ATP-dependent, also producing pyrophosphate and AMP as byproducts. Previous research suggests that BaiB acts upon bile acids with a free C-24 group. baiB shares amino acid homology with the Escherichia coli entE gene, coding for 2,3-dihydroxybenzoate-AMP ligase, and the Bifidobacterium brevis grsA and tycA genes, encoding Gramicidin S synthetase 1 and Tyrocidine synthetase 1 respectively. baiA2 (3-ɑ-hydroxysteroid dehydrogenase): The next enzyme to act after baiB, baiA2 catalyzes the oxidation of the C-3 hydroxyl group into a carbonyl group. This enzyme replaces the hydroxyl (-OH) group with a carbonyl (C=O) group. This enzyme is part of a short-chain dehydrogenase/reductase enzyme family that characteristically requires a NAD+/NADP+ cofactor for functionality. Research into the cofactor binding site of baiA2 has revealed that it specifically uses NAD+ due to its structure.
== Medical uses == Tazarotene is most commonly used topically to treat acne vulgaris, psoriasis, and photoaging. Like other topical retinoids, such as tretinoin and adapalene, tazarotene can be used in a regimen with benzoyl peroxide and/or an oral antibiotic, such as clindamycin or dapsone, for the treatment of acne. This results in increased efficacy compared to tazarotene monotherapy. Combination therapy utilizing tazarotene alongside a mid- to high-potency corticosteroid is more effective in treating psoriasis compared to monotherapy of either drug. Tazarotene can also be used for the treatment of photodamaged skin. It can reduce the histological and clinical signs of photodamaged skin, such as fine lines, wrinkles, hyperpigmentation, and lentigo. The therapy is more effective when used with the daily application of sunscreen.
Sources: en.wikipedia.org
=== New Zealand in 1998 === In 1998 he walked from Cape Reinga in the North Island, to Bluff, at the southern tip of New Zealand; a distance of 1,500 miles (2,400 km). On the journey he walked through the active volcano at White Island, experienced earthquakes up to 4.9 on the Richter Scale, clambered over glaciers, swam with seals and reported on conservation biology projects involving endangered species. Information from the journey was posted on the Internet for schoolchildren in the U.S. via the Scholastic Corporation Scholastic Network. In December 2010 Skinner completed a book about the journey and conservation biology, New Zealand – 1500 miles on foot through – The Land of the Long White Cloud on an Internet website. In 1999 he obtained a PGCE (Postgraduate Certificate in Education) from Canterbury Christ Church University in Canterbury, England. In 2000 he worked as a secondary school science teacher at St. Edmund's School in Dover, teaching 11 to 16-year-olds. In 2001 he worked as a volunteer at a wildlife park, working on enrichment activities for animals. From 2001 until 2003 he worked part-time at a post office. During this time, he also taught science to primary school children, in a 'Link-Scientist' scheme run by the pharmaceutical company Pfizer, and took care of his son. In 2003 his mother died from pancreatic cancer, at the age of 59. This prompted him to write the story of the 6,000 miles (9,700 km) journey across Britain and America.
=== Anion exchange resins === Strong base anion (SBA) resins: Type 1 SBA resins: Greatest affinity for the weak acids and commonly present during a water demineralization process. Type 3 SBA resins: Lower chemical stability than Type 1 but better regeneration efficiency. Weak base anion (WBA) resins: Act as acid absorbers; capable of sorbing strong acids with a high capacity and are readily regenerated with caustic.
Roma Elimaude Taylor. For services to Community Cohesion in Cardiff. Dean Mark Terrett. For services to Search and Rescue on the Isle of Wight. Sally Carmichael Thomas JP. For services to the community in Merthyr Tydfil. Janet Alexandra Thompson. For services to the Scouting Movement in Northern Ireland. Kirsty Elizabeth Tilley. Programme Manager, Defence Science and Technology Laboratory, Ministry of Defence. For services to Defence and to Inclusion. David Alwyn Town. For services to Bell Ringing in Northallerton and North Yorkshire. Richard William Townsend. Lately Community Coach, Milton Keynes Athletics Club. For services to Sport and to the communities in Milton Keynes and South Yorkshire. Mary Elisabeth Trigwell-Jones. For services to the community in East Worldham, Hampshire. Jill Trout. For services to the community in Dockenfield, Surrey. Stephen John Vale. For services to the community in West Stow, Suffolk. Marco Antonio Valencia. Operations Assistant, London Borough of Sutton. For services to Local Government. Bernard Vause. For services to Music and to the community in Morecambe, Lancashire. Debra Ruth Veigas. End of Life Care Admiral Nurse, Wakefield Hospice and Dementia UK. For services to People with Dementia and to End of Life Care in Wakefield, West Yorkshire. Dr Ian Gordon Vincent. President, Nottingham Croquet Club. For services to Croquet. Alice Kerr Waite. Officer, Girls' Brigade. For services to Young People and to the community in Cambuslang, Lanarkshire. Darren Walker. For services to the community in Leeds, West Yorkshire. Florence Diane Walker.
=== Improvement === To help promote and expand the adoption of health information technology, Congress passed the HITECH act as part of the American Recovery and Reinvestment Act of 2009. HITECH stands for Health Information Technology for Economic and Clinical Health Act. It gave the department of health and human services the authority to improve healthcare quality and efficiency through the promotion of health IT. The act provided financial incentives or penalties to organizations to motivate healthcare providers to improve healthcare. The purpose of the act was to improve quality, safety, efficiency, and ultimately to reduce health disparities. One of the main parts of the HITECH act was setting the meaningful use requirement, which required EHRs to allow for the electronic exchange of health information and to submit clinical information. The purpose of HITECH is to ensure the sharing of electronic information with patients and other clinicians are secure. HITECH also aimed to help healthcare providers have more efficient operations and reduce medical errors. The program consisted of three phases. Phase one aimed to improve healthcare quality, safety and efficiency. Phase two expanded on phase one and focused on clinical processes and ensuring the meaningful use of EHRs. Lastly, phase three focused on using Certified Electronic Health Record Technology (CEHRT) to improve health outcomes. In 2014, the implementation of electronic records in US hospitals rose from a low percentage of 10% to a high percentage of 70%.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。